SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as reports surface of unsolicited takeover interest from rivals, some eyeing the entire company while others target specific assets like Venmo or Braintree following its significant stock slump. The community is actively debating potential buyers and buyout prices, largely driven by the belief that the fintech giant is fundamentally undervalued given its substantial free cash flow and ongoing share buyback program.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike faces a sharp sell-off across the cybersecurity sector, driven by market fears that Anthropic's new AI code security tool will disrupt traditional offerings. The community is fiercely debating whether this is an irrational overreaction, with many highlighting CRWD's distinct endpoint and cloud security services and arguing that AI-driven threats will actually increase demand for established cybersecurity leaders.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting overwhelmingly positive Phase 2 clinical trial results for sonelokimab in axial spondyloarthritis, demonstrating significant efficacy and potential disease modification ahead of its Investor Day. Despite this "game-changing" data and the company's strong cash runway, the community is actively discussing market "sell the news" behavior and perceived manipulation amidst significant short interest.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is experiencing heightened trading activity following the FDA approval of its BYSANTI drug for bipolar I disorder and schizophrenia, which notably secured New Chemical Entity status and patent protection until 2044. The community is buzzing with discussions about the stock's significant undervaluation, pointing to its strengthened pipeline and past rejected buyout offers, fueling expectations for a substantial re-rating and potential M&A interest from larger pharmaceutical companies.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point as President Trump files a $5 billion lawsuit against the bank and CEO Jamie Dimon, alleging politically motivated account closures, a move that follows Dimon's public criticism of Trump's proposed credit card rate cap and fuels community debate over broader financial sector pressures.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is a major talking point as its impending earnings report follows recent news of a 12% workforce reduction, fueling intense community debate over the stock's persistent new all-time lows and the company's financial outlook in the competitive EV sector.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit (INTU) is a hot topic as it experiences a dramatic sell-off, with its stock plummeting due to widespread market fears that generative AI will significantly disrupt its core tax and accounting software businesses. Community discussion, however, is sharply divided, with many viewing the heavily oversold conditions as a prime buying opportunity, believing AI will enhance rather than replace Intuit's strong ecosystem ahead of its upcoming earnings.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF ($IGV) is experiencing a significant sell-off and hitting new lows, fueled by widespread community fear that Anthropic's Claude AI tools will disrupt and replace traditional software. This "SaaS-pocalypse" is sparking intense debate among investors over whether the market's aggressive reaction is an overblown narrative or a fundamental threat.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is facing intense selling pressure, hitting new lows, as the cybersecurity sector grapples with fears that AI tools like Anthropic's Claude Code Security could disrupt existing solutions, prompting community debate between panic selling and 'buy the dip' opportunities ahead of its earnings report.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as the broader software sector sell-off weighs heavily, prompting community debate on whether market fears about AI's disruptive potential are irrationally impacting this AI-driven marketing platform ahead of its highly anticipated earnings report. Despite a consistent streak of financial beats and a proprietary data "moat", investors are grappling with extreme volatility and a perceived disconnect between strong fundamentals and current stock performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low after the company announced a significant setback for its lead drug candidate, AK006.The biotech company revealed it would cease further clinical development of AK006 after its preclinical inhibitory effects failed to translate into clinical benefits for patients with chronic spontaneous urticaria (CSU).In the proof-of-concept trial, 34 adult patients with moderate-to-severe CSU refractory to antihistamines, with or without prior omalizumab exposure, were randomized 2:1 to receive AK006 or placebo.&nbsp;The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.&nbsp;The company will retain a small team of about 15 employees to explore strategic alternatives, ensure compliance, and oversee the wind-down of its phase 1 trial.Allakos ended the fourth quarter of 2024 with $81 million in cash and expects restructuring costs of $34–$38 million, primarily to be paid by mid-2025.&nbsp;The company estimates its cash reserves will decline to $35–$40 million by June 30, 2025.Following the announcement, several analysts adjusted their outlook on Allakos, according to The Fly.Piper Sandler downgraded the stock to ‘Neutral’ from ‘Overweight,’ slashing its price target to $0.30 from $7. The brokerage noted AK006 was Allakos’s sole asset, leaving the remaining valuation restricted to cash.JMP Securities downgraded Allakos to ‘Market Perform’ from ‘Outperform’.On Stocktwits, sentiment for Allakos shifted sharply to ‘bearish’ as disappointed retail investors voiced their concerns.&nbsp;<stembedurl>https://stocktwits.com/Majlo97/message/601635808</stembedurl><stembedurl>https://stocktwits.com/subieroo_wrx/message/601634053</stembedurl>Data showed declining interest in the stock, with a 4.6% drop in followers over the past year and a 44% reduction in message volume last week.<a href="https://stocktwits.com/symbol/ALLK">Allakos stock</a> has now lost 77% over the past 12 months, reflecting mounting challenges for the small-cap biotech as it faces an uncertain future.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade

The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.

Equity

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

ALLK
Allakos Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALLK News

ALLKAllakos Inc